CARDIOVASCULAR MEDICINE: Edited by Daniel BernsteinPrevention of adverse drug effects: a pharmacogenomic approachScott, Erika N.a,b,∗; Hasbullah, Jafar S.a,b,∗; Carleton, Bruce C.b,c,d; Ross, Colin J.D.a,b,eAuthor Information aDepartment of Medical Genetics, Faculty of Medicine, University of British Columbia bBritish Columbia Children's Hospital Research Institute cDivision of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia dPharmaceutical Outcomes Programme, British Columbia Children's Hospital eFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada Correspondence to Colin J.D. Ross, MSc, PhD, Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, Canada V6T 1Z3. Tel: +1 604 827 2017; e-mail: [email protected] Current Opinion in Pediatrics: October 2020 - Volume 32 - Issue 5 - p 646-653 doi: 10.1097/MOP.0000000000000935 Buy Metrics Abstract Purpose of review Adverse drug reactions (ADRs) are a serious burden and can negatively impact patient quality of life. One of these ADRs, anthracycline-induced cardiotoxicity (ACT), occurs in up to 65% of treated patients and can lead to congestive heart failure. Pharmacogenetic studies have helped to reveal the mechanisms of ACT and, consequently, inform current strategies to prevent ACT in the clinic. Recent findings Many pharmacogenetic studies have been conducted for ACT, but few have led to the development of clinical practice guidelines and clinical genetic testing for ACT. This is, in part, because of lack of replication in independent patient cohorts and/or validation of an affected biological pathway. Recent advances in pharmacogenetic studies have been made through the use of novel methods that directly implicate dysregulated genes and perturbed biological pathways in response to anthracycline treatment. Summary Furthering the understanding of the genetics and altered biological pathways of ACT through these novel methods can inform clinical treatment strategies and enable refinement of current clinical practice guidelines. This can therefore lead to improvement in clinical pharmacogenetic testing for further reduction of the incidence of ACT in pediatric cancer patients taking anthracyclines. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.